Literature DB >> 10693635

Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis.

D L Paterson1, T Gayowski, C F Wannstedt, M M Wagener, I R Marino, H Vargas, T Laskus, J Rakela, N Singh.   

Abstract

Post liver transplant recurrence of infection with hepatitis C virus (HCV) occurs in approximately 50% of patients transplanted because of HCV-related liver disease. The aim of this study was to assess long-term quality of life, psychologic distress, and coping in patients with recurrent HCV after liver transplantation in comparison to patients transplanted for other etiologies of underlying liver disease. All liver transplant recipients transplanted at a University affiliated Veterans Affairs Medical Center who had greater than 6 months follow-up were sent a questionnaire investigating quality of life (assessed by Medical Outcomes study health survey SF-36), depression (assessed by Beck Depression Inventory), total mood disturbance (assessed by Profile of Mood States scale), coping (assessed by Billing and Moos Inventory of coping with illnesses), and employment status. Lower Beck Depression Inventory score (p = 0.001), lower mood disturbance score (p = 0.0001), overall satisfaction with present work (p = 0.0001), and lesser use of avoidant coping (p = 0.06) were predictors of better quality of life in long-term survivors of liver transplantation. At a mean follow-up of 4 yr after liver transplantation, patients with histopathologically diagnosed recurrent viral HCV hepatitis had significantly lower global quality of life score (mean score of 76.4 versus 86.2, p = 0.011) and physical functioning score (mean score 20 versus 25, p = 0.015), as compared to all other patients. In summary, quality of life and physical functioning were significantly impaired in liver transplant recipients with histopathologically diagnosed recurrent HCV hepatitis, as compared to those whose HCV hepatitis had not recurred or those transplanted for other reasons.

Entities:  

Mesh:

Year:  2000        PMID: 10693635     DOI: 10.1034/j.1399-0012.2000.140109.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  8 in total

Review 1.  The impact of liver disease on health-related quality of life: a review of the literature.

Authors:  Lisa M Martin; Michael J Sheridan; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2002-02

2.  Prevalence and predictors of sleep disturbance among liver diseases in long-term transplant survivors.

Authors:  Mamatha Bhat; Jonathan M Wyse; Erica Moodie; Peter Ghali; Nir Hilzenrat; Philip Wong; Marc Deschenes
Journal:  Can J Gastroenterol Hepatol       Date:  2015-07-15

3.  High levels of subgenomic HCV plasma RNA in immunosilent infections.

Authors:  Flavien Bernardin; Susan L Stramer; Barbara Rehermann; Kimberly Page-Shafer; Stewart Cooper; David R Bangsberg; Judith Hahn; Leslie Tobler; Michael Busch; Eric Delwart
Journal:  Virology       Date:  2007-05-09       Impact factor: 3.616

4.  Profile of health-related quality of life outcomes after liver transplantation: univariate effects and multivariate models.

Authors:  R T Russell; I D Feurer; P Wisawatapnimit; E S Lillie; E T Castaldo; C Wright Pinson
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

5.  Quality of life after liver transplantation for hepatitis C infection.

Authors:  Tracey Dudley; Dawn Chaplin; Collette Clifford; David John Mutimer
Journal:  Qual Life Res       Date:  2007-07-31       Impact factor: 4.147

Review 6.  Management of hepatitis C infection after liver transplantation.

Authors:  Mazen Alsatie; Naga Chalasani; Paul Y Kwo
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

Authors:  Susan Zickmund; Evelyn Y Ho; Masahiro Masuda; Laura Ippolito; Douglas R LaBrecque
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

8.  Liver transplantation for hepatitis C and alcoholic liver disease.

Authors:  Marco Carbone; James Neuberger
Journal:  J Transplant       Date:  2010-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.